These findings align with growing evidence indicating that SGLT2 inhibitors may have liver-protective effects, potentially by reducing hepatic steatosis, inflammation, or fibrosis in patients with T2DM and NAFLD [15]. This evidence concerns the gene SLC5A2 and fatty liver disease.